BeiGene, Ltd. (NASDAQ:BGNE) Receives Consensus Rating of "Moderate Buy" from Brokerages

BeiGene, Ltd. (NASDAQ:BGNE - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven brokerages that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $247.07.

Several research firms recently issued reports on BGNE. StockNews.com cut BeiGene from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. JMP Securities initiated coverage on BeiGene in a research report on Wednesday, September 18th. They set a "market outperform" rating and a $288.00 price target for the company. TD Cowen raised their price objective on BeiGene from $254.00 to $260.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. Citigroup upped their target price on shares of BeiGene from $269.00 to $288.00 and gave the stock a "buy" rating in a report on Thursday, August 8th. Finally, JPMorgan Chase & Co. increased their target price on shares of BeiGene from $200.00 to $235.00 and gave the company an "overweight" rating in a research report on Tuesday, October 22nd.

Insider Activity

In other BeiGene news, insider Titus B. Ball sold 137 shares of the business's stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $189.94, for a total value of $26,021.78. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Xiaobin Wu sold 5,556 shares of the firm's stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $189.65, for a total value of $1,053,695.40. The disclosure for this sale can be found here. Insiders have sold a total of 63,538 shares of company stock valued at $12,594,017 in the last quarter. Insiders own 7.43% of the company's stock.

Institutional Trading of BeiGene

Several hedge funds have recently made changes to their positions in BGNE. Blue Trust Inc. increased its stake in BeiGene by 156.3% during the 3rd quarter. Blue Trust Inc. now owns 123 shares of the company's stock worth $28,000 after buying an additional 75 shares during the period. Allspring Global Investments Holdings LLC purchased a new stake in shares of BeiGene during the third quarter worth $36,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of BeiGene in the third quarter valued at $67,000. SG Americas Securities LLC purchased a new position in BeiGene in the third quarter valued at $105,000. Finally, PFG Investments LLC acquired a new position in BeiGene during the 3rd quarter worth $210,000. Institutional investors and hedge funds own 48.55% of the company's stock.

BeiGene Price Performance

BeiGene stock traded up $8.84 during trading on Friday, reaching $215.00. The company had a trading volume of 258,633 shares, compared to its average volume of 266,091. The firm has a market capitalization of $20.94 billion, a PE ratio of -26.09 and a beta of 0.63. The firm's 50-day simple moving average is $212.42 and its 200 day simple moving average is $184.63. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93. BeiGene has a 1-year low of $126.97 and a 1-year high of $248.16.

BeiGene (NASDAQ:BGNE - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.04). The company had revenue of $1 billion for the quarter, compared to analysts' expectations of $983.26 million. BeiGene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The business's revenue for the quarter was up 28.2% on a year-over-year basis. During the same period in the previous year, the business earned $2.01 earnings per share. As a group, equities research analysts anticipate that BeiGene will post -5.38 earnings per share for the current fiscal year.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.